IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kathleen A. Elias Attorney Docket No.: CYTOP002D1

Application No.: NEW Examiner: UNASSIGNED

Filed: HEREWITH Group: UNASSIGNED

Title: METHOD OF CHARACTERIZING

POTENTIAL THERAPEUTICS BY

DETERMINING CELL-CELL

INTERACTIONS

8/7/02

INFORMATION DISCLOSURE STATEMENT 37 CFR §§1.56 AND 1.97(b)

Commissioner for Patents Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449 may be material to examination of the above-identified patent application. Applicants submit the list of these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application. The above-identified application is a Divisional of prior application U.S. Patent Application No. 09/741,721. This prior application is being relied upon for an earlier filing date under 35 U.S.C. § 120. Because the listed references were either cited by the PTO, or submitted to the PTO in the prior application, under 37 CFR § 1.98(d) Applicants submit that copies need not be provided.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure

Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. <u>CYTOP002D1</u>).

Respectfully submitted,

BEYER WEAVER & THOMAS, LLP

Jeffrey K. Weaver

Registration No. 31,314

P.O. Box 778 Berkeley, CA 94704-0778

1'. ...

			2 =
Form 1449 (Modified)	Atty Docket No.	Application No.:	
	CYTOP002D1	NEW	
Information Disclosure	Applicant:		
Statement By Applicant	Kathleen A. Elias		######################################
	Filing Date	Group	
(Use Several Sheets if Necessary)	HEREWITH	UNASSIGNED	ň ==

U.S. Patent Documents

Examiner	1					Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	class	Date
	A1	6,008,010	12/28/99	Greenberger et al.			
	A2	5,989,835	11/23/99	Dunlay et al.			
	A3	60/120,801	02/19/99	Wang et al.			
	A4	60/142,646	07/06/99	Boyce et al.			
	A5	60/142,375	07/06/99	Boyce et al.			
	A6	60/108,291	11/13/98	Boyce et al.			
	A7	60/110,643	12/01/98	Smith			
	A8	60/140,240	06/21/99	Dunlay et al.			
	A9	5,655,028	08/05/97	Soll			
	A10	5,976,825	11/2/99	Hochman			1
	A11	5,804,436	09/08/98	Okun et al.			-
	A12	5,919,646	07/06/99	Okun et al.			
	A13	6,103,479	08/15/00	Taylor			
	A14	4,965,725	10/23/90	Rutenberg			
	A15	5,741,648	04/21/98	Hemstreet et al.			1
	A16	5,991,028	11/23/99	Cabib et al.		†	
	A17	6,007,996	12/28/99	McNamara et al.			
	A18	5,548,661	08/20/96	Price et al.			
	A19	5,790,692	08/04/98	Price et al.			
	A20	5,790,710	08/04/98	Price et al.		1	
	A21	5,856,665	01/05/99	Price et al.			
	A22	5,932,872	08/13/99	Price	1		
	A23	5,995,143	11/30/99	Price et al.			<u> </u>
	A24	5,776,748	06/07/98	Singhvi et al.			
	A25	4,959,301	09/25/90	Weaver et al.			
	A26	5,962,520	10/05/99	Gavin et al.			
	A27	6,007,996	12/28/99	McNamara		1	

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	B1	WO 99/39184	08/05/99	PCT			X	
	B2	WO 00/29984	05/25/00	PCT			X	
	В3	WO 98/45704	10/15/98	PCT			X	

Form 1449 (Modified)	Atty Docket No. CYTOP002D1	Application No.: NEW
Information Disclosure Statement By Applicant	Applicant: Kathleen A. Elias	
(Use Several Sheets if Necessary)	Filing Date HEREWITH	Group UNASSIGNED

B4	WO 99/17116	04/08/99	PCT	X
B5	WO 99/54494	10/28/99	PCT	X
B6	WO 98/05959	02/12/98	PCT	X
B7	WO 00/33250	06/08/00	PCT	X
B8	WO 00/03246	01/20/00	PCT	X
B9	WO 00/17624	03/30/00	PCT	X
B10	WO 00/17643	03/30/00	PCT	X
B11	WO 00/50872	08/31/00	PCT	X
B12	WO 00/60356	10/12/00	PCT	X
B13	WO 97/45730	12/04/97	PCT	X
B14	WO 98/38490	09/03/98	PCT	X
B15	WO 97/20198	06/05/97	PCT	X
B16	WO 98/44333	10/08/98	PCT	X
B17	WO 99/44062	09/02/99	PCT	X
B18	EP 0468705	01/29/92	EP	X
B19	EP0902394	03/17/99	EP	X
B20	WO 00/06774	02/10/00	PCT	X
B21	WO 00/17808	03/30/00	PCT	X
B22	WO 00/26408	05/11/00	PCT	X
B23	WO 00/31534	06/02/00	PCT	X
B24	WO 95/10036	04/13/95	PCT	X
B25	WO 99/67739	12/29/99	PCT	X
B26	WO 87/02802	05/07/87	PCT	X
B27	WO 99/08091	02/18/99	PCT	X
B28	WO 00/49540	08/24/00	PCT	X
B29	WO 00/43820	07/27/00	PCT	X
B30	WO 96/01438	01/18/96	PCT	X
B31	WO 98/35256	08/13/98	PCT	X
B32	WO 97/40055	10/30/97	PCT	X
B33	WO 99/39184	08/05/99	PCT	X
B34	EP0902394A1	03/17/99	EP	X

Form 1449 (Modified)	Atty Docket No.	Application No.:
	CYTOP002D1	NEW
Information Disclosure	Applicant:	
Statement By Applicant	Kathleen A. Elias	
1	Filing Date	Group
(Use Several Sheets if Necessary)	HEREWITH	UNASSIGNED

Other Documents

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	C1	Printout from Q3DM Website (www.Q3DM.com), printed on March 1, 2001,
		30 Pages.
	C2	Montironi R., et al., "Computed Cell Cycle and DNA Histogram Analyses in
		Image Cytometry in Breast Cancer", Journal of Clinical Pathology, GB,
		London, Vol. 46, No. 9, September 1993, Pages 795-800.
	C3	Giuliano K.A., et al., "Fluorescent-Protein Biosensors: New Tools for Drug
	1	Discovery", Trends in Biotechnology, GB, Elsevier Publications, Cambridge,
		Vol. 16, No. 3, March 1998, Pages 135-140.
	C4	Printout from Automated Cell Website (www.automatedcell.com) printed on
		March 9, 2001, 24 Pages.
	C5	Ravi Kapur, et al., "Design and Fabrication of Spatially Controlled
•		Miniaturized Organ Systems From Stem Cells", U.S. Provisional Patent
		Application No.: 60/127,339, Filed April 1, 1999, 21 Pages.
-	C6	Giuliano et al., "High-Content Screening: A New Approach to Easing Key
	ļ	Bottlenecks in the Drug Discovery <u>Process</u> ", J. <u>Biomolecular Screening</u> , 2(4):
1		249 (1997).
	C7	Pauwels et al., "Determination of the Mechanism of Action of Anticancer
İ	1	Drugs by Means of the Computer- Assisted Microscope Image Analysis of
1		Feulgen-Stained Nuclei", J. Pharmacological and Toxicological Methods. 37:
ł		105-115 (1997).
	C8	Pauwels et al., "Monitoring Of Chemotherapy-Induced Morphonuclear
ļ		Modifications By Means Of Digital Cell-Image
		Analysis", I. Cancer Res. Clin. Oncol., 119: 533-540 (1993).
	C9	Pauwels et al., "In Vitro Digital Cell Image Analysis of Morphonuclear
		Modifications Induced by Natural DNA- Interacting Anticancer Drugs in
		Three Neoplastic Cell Lines", Meth. Find. Exp. Clin. Pharmacol 17(3): 151-
		161 (1995).
		<u></u>

Form 1449 (Modified)	Atty Docket No. CYTOP002D1	Application No.: NEW
Information Disclosure	Applicant:	
Statement By Applicant	Kathleen A. Elias	
	Filing Date	Group
(Use Several Sheets if Necessary)	HEREWITH	UNASSIGNED

C	10 Pauwels et al.	., "The Application of Computerized Analysis of Nuclear Images			
		iate Analysis to the Understanding of the Effects of			
1	Antineoplasti	Antineoplastic Agents and Their Mechanism of Action", Meth. Find. Exp.			
	Clin. Pharmad	col, 15(2): 113-124 (1993).			
C		et al., "Cell Patterning on Glass and Polymeric Substrates", U.S.			
		Patent Application No.: 60/127,138,119, Filed June 7, 1999, 21			
	Pages.				
C		ed Method to Determine Epithelial Transport and Bioactivity of			
	Oral Drug Ca	andidates in Vitro," Pharmaceutical Research, Vol. 13, No. 1,			
	Pages 23-27,	1996			
C		ile-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C, "Regulation of			
	Collagenase-3	Collagenase-3 Expression in Human Breast Carcinomas in Mediated by			
,	Stromal-Epith	Stromal-Epithelial Cell Interactions", Cancer Res 1997 Nov 1;57 (21):4882-8,			
	Abstract				
C	14 Pauwels et al.	., "Combination of Computerized Morphonuclear and			
	Multivariate A	Analyses to Characterize In Vitro the Antineoplastic Effect of			
	Alkylating Ag	Alkylating Agents", J. Pharmacol. and Toxicol. Methods, 33(1): 34-45 (1995).			
C	15 Weinstein et				
{	Pharmacology	Pharmacology of Cancer", Science, 275: 43-349 (January 17, 1997).			
Examiner		Date Considered			

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.